Rasna Incorporation

Rasna Therapeutics, founded in 2013, is dedicated to developing innovative therapeutics for acute myeloid leukemia (AML) and other life-threatening leukemias. The company focuses on addressing the significant unmet medical needs in this area through its clinical programs that target key cancer regulators to enhance the safety and efficacy of current treatment options.

Headquartered in New York with research facilities in Doylestown, Pennsylvania, Rasna is publicly traded on the OTCQB under the ticker RASP. Its pipeline includes promising drug candidates, such as RASP-201 and RASP-301, aimed at improving outcomes for patients suffering from AML, a disease characterized by rapid progression and a low five-year survival rate.

Generated from the website